Pfizer Oncology Data Presentation Fact Sheet

advertisement
Pfizer Oncology Data Presentations at the American Association for Cancer Research (AACR)
Annual Meeting 2016
The embargo on most data lifted on Wednesday, March 16, at 4:30 p.m. ET unless otherwise noted.
At the American Association for Cancer Research (AACR) Annual Meeting 2016, multiple Pfizer-sponsored abstracts will
be presented highlighting clinical progress for seven Pfizer Oncology assets. The presentations span multiple tumor types
and mechanisms of action.1
Palbociclib:
(Abstract LB-196) A phase I open-label fixed-sequence two-period crossover study of the effect of multiple doses
of Itraconazole on palbociclib (PD‑0332991) pharmacokinetics in healthy volunteers. Hoffman J. Monday, April 18.
Session Type: Late-Breaking Poster. Display Time: 1:00 p.m. – 5:00 p.m. CT. Location: Section 12; Poster Board: 3.
(Embargoed until Friday, April 15).
(Abstract LB-198) A phase I open-label fixed-sequence two-period crossover study of the effect of multiple doses
of modafinil on palbociclib (PD-0332991) pharmacokinetics in healthy volunteers. Hoffman J. Monday, April 18.
Session Type: Late-Breaking Poster. Display Time: 1:00 p.m. – 5:00 p.m. CT. Location: Section 12; Poster Board: 5.
(Embargoed until Friday, April 15).
(Abstract 2740) Mechanistic basis of Palbociclib combinatorial activity in ER+ breast cancer and non-breast
indications. Dann S. Tuesday, April 19. Session Type: Poster. Display Time: 8:00 a.m. – 12:00 p.m. CT. Location:
Section 2; Poster Board: 28.
(Abstract 2826) Sustained melanoma regression is achieved with continuous palbociclib and PLX4720 treatment
but not with intermittent or sequential dosing. Sheppard K. Tuesday, April 19. Session Type: Poster. Display Time:
8:00 a.m. – 12:00 p.m. CT. Location: Section 6; Poster Board: 12
Early-Pipeline Assets
Gedatolisib (PF-05212384):
(Abstract 2278) Next-generation sequencing (NGS) analysis from a phase II single-agent gedatolisib study in
patients with endometrial cancer. Pathan N. Monday, April 18. Session Type: Poster. Display Time: 1:00 p.m. – 5:00
p.m. CT. Location: Section 23; Poster Board: 10.
Anti-NG-HER2 ADC (PF-06804103):
(Abstract 868) Creating a superior, site-specific anti-HER2 antibody-drug conjugate (NG-HER2 ADC) for treatment
of solid tumors. Ma D. Sunday, April 17. Session Type: Oral. Presentation Time: 4:35 p.m. – 4:50 p.m. CT. Location:
Room 265.
1
Anti-NOTCH3 ADC (PF-06650808):
(Abstract 1206) Preclinical evaluation of targeting Notch-3 in breast cancer. Hurvitz S. Monday, April 18. Session
Type: Poster. Display Time: 8:00 a.m. – 12:00 p.m. CT. Location: Section 15; Poster Board: 15.
EGFR T790M (PF-06747775):
(No Abstract) Reducing proteome reactivity of irreversible EGFR T790M inhibitors. Kath J. Tuesday, April 19.
Session Type: Major Symposium. Presentation Time: 11:40 a.m. – 12:05 p.m. CT. Location: Room 343.
IDO-1 (PF-06840003):
(Abstract 4863) PF-06840003: a highly selective IDO-1 inhibitor that shows good in vivo efficacy in combination
with immune checkpoint inhibitors. Tumang J. Wednesday, April 20. Session Type: Poster. Display Time: 8:00 a.m. –
12:00 p.m. CT. Location: Section 22; Poster Board: 4.
PTK7 ADC (PF-06647020):
(Abstract 1220) A novel PTK7-targeted antibody-drug conjugate eliminates tumor-initiating cells and induces
sustained tumor regressions. Damelin M. Monday, April 18. Session Type: Poster. Display Time: 8:00 a.m. – 12:00 p.m.
CT. Location: Section 15; Poster Board: 29.
Other Research
(Abstract 847) Molecular characterization of breast tumor T-cell infiltration in exome datasets. Harismendy O.
Sunday, April 17. Session Type: Oral. Presentation Time: 4:35 p.m. – 4:50 p.m. CT. Location: Room 243.
(Abstract 4384) Selective cross-cohort discovery of transcriptional mechanisms presiding over high-risk
neuroblastoma subtype state maintenance. Rajbjandari P. Tuesday, April 19. Session Type: Oral. Presentation Time:
4:05 p.m. – 4:20 p.m. CT. Location: New Orleans Theater A.
(Abstract 2113) Caveolae-mediated endocytosis as a novel mechanism of resistance to T-DM1 ADC. Sung M.
Monday, April 18. Session Type: Poster. Display Time: 1:00 p.m. – 5:00 p.m. CT. Location: Section 17; Poster Board: 11.
(Abstract 2092) Characterizing NIR dye-IL13RA2 antibody conjugates for biodistribution studies in xenograft
tumor models by fluorescence molecular tomography (FMT). Gupta P. Monday, April 18. Session Type: Poster.
Display Time: 1:00 p.m. – 5:00 p.m. CT. Location: Section 16; Poster Board: 13.
(Abstract 2328) ICOS signaling promotes CD4+ effector T-cell function during antitumor responses. Metzger T.
Monday, April 18. Session Type: Poster. Display Time: 1:00 p.m. – 5:00 p.m. CT. Location: Section 26; Poster Board: 12.
(Abstract 4143) Characterizing the immunogenicity of gastric cancer by transcriptomic expression based immune
phenotyping. Wang K. Tuesday, April 19. Session Type: Poster. Display Time: 1:00 p.m. – 5:00 p.m. CT. Location:
Section 31; Poster Board: 10.
2
(Abstract 5279) The first ACT: an efficient data tracking and sharing tool for ADC and linker-payload development.
Loganzo F. Wednesday, April 20. Session Type: Poster. Display Time: 8:00 a.m. – 12:00 p.m. CT. Location: Section 37;
Poster Board: 16.
###
1
The AACR Annual Meeting 2016 Website. Search Program / Itinerary Planner:
http://www.abstractsonline.com/plan/start.aspx?mkey=%7b1D10D749-4B6A-4AB3-BCD4-F80FB1922267%7d. Accessed March 16, 2016
3
Download